Pacific International Journal, Vol. 7(4); 2024
ISSN (Print) 2663-8991, ISSN (Online) 2616-4825[1]
DOI:10.55014/pij.v7i4.652
https://rclss.com/index.php/pij

Application of Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Peripheral T-cell Lymphoma

Xuewen Lei[1], Hua Li[1*]
[1]Peking University Cancer Hospital Inner Mongolia Hospital ,Hohhot, China
Email: 1692140640@qq.com;
[*]Corresponding Author:lihuahuanhuan@163.com

Abstract: Peripheral T-cell lymphoma (PTCL) is a subset of non-Hodgkin lymphoma that poses significant treatment challenges. Improving treatment strategies and prognosis for PTCL has been a major focus of research. Autologous hematopoietic stem cell transplantation (Auto-HSCT) has gained significant attention in recent years as a crucial therapeutic approach for PTCL. This paper reviews the literature and analyzes clinical data to explore the value, treatment process, efficacy evaluation, and management of complications associated with Auto-HSCT in PTCL. Studies indicate that Auto-HSCT can significantly improve disease-free survival (DFS) and overall survival (OS) in some PTCL patients, particularly those who undergo transplantation after initial remission. Additionally, this paper discusses the risk assessment and management strategies for complications arising during the transplantation process. The potential for combining Auto-HSCT with emerging therapies such as CAR-T cell therapy is also examined. Despite certain limitations, Auto-HSCT holds an indispensable role in the comprehensive treatment of PTCL and offers new directions for future research.
Keywords: autologous hematopoietic stem cell transplantation, peripheral T-cell lymphoma, efficacy, complications, treatment strategy

Introduction1. Introduction

1.1 Overview of Peripheral T-cell Lymphoma

Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of non-Hodgkin lymphomas originating from mature T cells, accounting for 10-15% of all lymphomas. PTCL includes multiple subtypes, each with unique clinical manifestations and biological characteristics. Compared to B-cell lymphomas, PTCL generally exhibits higher aggressiveness, poorer response to conventional chemotherapy, and worse prognosis. Therefore, PTCL treatment strategies require more precise and individualized approaches to improve patient survival and outcomes.

1.2 Basic Concept of Autologous Hematopoietic Stem Cell Transplantation

Autologous hematopoietic stem cell transplantation (Auto-HSCT) involves collecting and preserving a patient's own hematopoietic stem cells prior to administering high-dose chemotherapy or radiotherapy, followed by reinfusion of the preserved stem cells to restore hematopoietic function post-treatment. The goal of Auto-HSCT is to eliminate tumor cells through intensive therapy while using autologous stem cell reinfusion to reduce treatment-related toxicity and complications, thereby accelerating recovery.

1.3 Research Background and Current Status

Although progress has been made in lymphoma treatment in recent years, PTCL remains a therapeutic challenge due to its high heterogeneity and resistance to conventional therapies. Auto-HSCT has shown potential in improving survival rates for certain lymphoma types; however, its application in PTCL remains controversial, with efficacy and safety requiring further clinical evaluation. Additionally, issues such as patient selection, timing of transplantation, conditioning regimens, and complication management need further exploration.

2. Theoretical Basis of Autologous Hematopoietic Stem Cell Transplantation

2.1 Principles of Autologous Hematopoietic Stem Cell Transplantation

The core principle of Auto-HSCT is to utilize a patient's own hematopoietic stem cells to support recovery following high-dose chemotherapy or radiotherapy. This treatment involves collecting and preserving hematopoietic stem cells from peripheral blood or bone marrow. Subsequently, the patient undergoes high-intensity conditioning therapy aimed at eliminating as many cancer cells as possible, including potential minimal residual disease. Conditioning typically includes high-dose chemotherapy drugs and sometimes radiotherapy. Following this, the previously preserved autologous stem cells are reinfused to expedite the reconstruction of the hematopoietic system and restore immune function. This process, known as "engraftment," is crucial for the success of Auto-HSCT.

2.2 Advantages and Challenges of Autologous Hematopoietic Stem Cell Transplantation

The main advantage of Auto-HSCT lies in providing a treatment method with minimal risk of graft-versus-host disease (GVHD), as the patient's own cells are used. Additionally, the high-dose chemotherapy or radiotherapy can enhance the

[Received 12 May 2024; Accepted 12 August 2024; Published (online) 20, August, 2024]

tumor-killing effect, potentially leading to deeper remission. However, this approach also faces challenges, including the toxicity associated with conditioning therapy, transplant-related complications, and the fact that not all patients are suitable candidates for or can tolerate high-dose treatment.

2.3 Potential Mechanisms of Autologous Hematopoietic Stem Cell Transplantation in PTCL

The potential mechanisms of Auto-HSCT in PTCL may include:

- Enhanced Tumor Killing: High-dose chemotherapy or radiotherapy can increase the killing effect on PTCL cells, especially those that are less sensitive to conventional-dose chemotherapy.
- Immunomodulation: The transplantation process may impact the patient's immune system, including enhancing immune surveillance and tumor clearance.
- Rapid Recovery: The reinfusion of autologous stem cells aids in the rapid reconstruction of hematopoietic function, reducing post-treatment recovery time.
- Graft-versus-Tumor Effect: Although less pronounced in autologous transplants compared to allogeneic transplants, there may still be a graft-versus-tumor effect that helps eliminate residual tumor cells.

Auto-HSCT offers an intensified treatment option for PTCL, particularly for patients who respond poorly to conventional therapy. To maximize efficacy and minimize associated risks, individualized assessments are necessary to determine the optimal timing and conditioning regimen for transplantation.

3. Indications and Patient Selection for Autologous Hematopoietic Stem Cell Transplantation

3.1 Determining Indications

The indications for autologous hematopoietic stem cell transplantation (Auto-HSCT) are primarily based on the patient's disease status and treatment response. For patients with peripheral T-cell lymphoma (PTCL), Auto-HSCT is typically considered in the following scenarios: consolidation therapy after first complete remission (CR1) to reduce relapse risk; salvage therapy after achieving remission in relapsed or refractory PTCL following second-line or multiple-line treatments; and early intensive therapy during first-line treatment for high-risk patients[1]. Determining indications requires a comprehensive consideration of pathological subtypes, disease staging, patient age, and overall health status.

3.2 Patient Selection Criteria

Selecting suitable candidates for Auto-HSCT involves several criteria. Firstly, patients must have sufficient physical fitness to tolerate high-dose conditioning therapy. Secondly, patients should exhibit good organ function, particularly in the heart, lungs, liver, and kidneys. Additionally, patients must have an adequate quantity and quality of hematopoietic stem cells to ensure successful transplantation and engraftment. Moreover, patients should have robust social and psychological support systems to help them cope with the challenges of the transplantation process.

3.3 Risk Assessment and Prognostic Factors

Comprehensive risk assessment is crucial before deciding on Auto-HSCT. This includes evaluating the patient's age, comorbidities, disease stage, pathological subtype, molecular genetic features, and response to prior treatments. Assessing prognostic factors helps determine whether a patient is likely to benefit from Auto-HSCT and predicts relapse and survival outcomes post-transplant. Additionally, imaging results from PET-CT scans play a vital role in evaluating disease activity and guiding treatment decisions[2].

Considering these factors comprehensively, physicians and patients can collaboratively decide whether Auto-HSCT is the optimal treatment choice and develop a personalized treatment plan to achieve the best possible outcomes and quality of life.

4. Procedure and Technical Highlights of Autologous Hematopoietic Stem Cell Transplantation

4.1 Stem Cell Mobilization and Collection

Stem cell mobilization is the first step in the Auto-HSCT process. This typically involves using hematopoietic growth factors, such as granulocyte colony-stimulating factor (G-CSF), to increase the number of stem cells in the bone marrow and mobilize them into the peripheral blood. The mobilized stem cells are then collected through apheresis. The collected stem cells are processed and cryopreserved for subsequent transplantation. Successful stem cell mobilization and collection are crucial for transplant success, requiring monitoring of CD34+ cell counts and quality to assess collection efficacy[3].

4.2 Selection of High-Dose Chemotherapy Regimens

High-dose chemotherapy is the conditioning phase of Auto-HSCT, aiming to eliminate as many cancer cells as possible to create favorable conditions for stem cell transplantation. The choice of chemotherapy regimen depends on several factors, including disease characteristics, treatment history, patient age, physical fitness, and potential complications. Commonly used high-dose chemotherapy drugs include cyclophosphamide, carmustine, etoposide, cytarabine, and melphalan.. Sometimes, chemotherapy regimens are combined with other treatment modalities, such as radiation therapy or biologic therapy, to enhance the therapeutic effect[4].

4.3 Management of the Transplantation Process

Managing the transplantation process is key to ensuring the success of Auto-HSCT. Before stem cell reinfusion, patients undergo conditioning therapy, usually under sterile conditions to reduce infection risk. Stem cells are reinfused

intravenously, a relatively simple step, but requires close monitoring of the patient's vital signs and any adverse reactions. Post-transplant, patients need to recover in a closely monitored environment where healthcare providers promptly assess and address possible complications such as infections, bleeding, and organ dysfunction. Additionally, managing the patient's nutrition and psychological state is crucial.

Throughout the transplantation process, the collaboration of a multidisciplinary team, including hematologists, oncologists, transplant specialists, nurses, dietitians, and psychologists, is essential to provide comprehensive care and treatment for patients. With careful planning and meticulous management, Auto-HSCT can offer an effective treatment option for PTCL patients.

5. Efficacy Evaluation and Clinical Outcomes

5.1 Efficacy Evaluation Standards

Evaluating the efficacy of autologous hematopoietic stem cell transplantation (Auto-HSCT) is a critical aspect of treatment assessment. The evaluation standards are typically based on international guidelines for lymphoma treatment, such as those from the National Comprehensive Cancer Network (NCCN) or the European Organisation for Research and Treatment of Cancer (EORTC). The evaluation includes complete remission (CR), partial remission (PR), stable disease (SD), and progressive disease (PD). CR and PR are generally considered indicators of effective treatment, whereas SD and PD may suggest the need for further or alternative therapies[5]. Additionally, imaging techniques such as PET-CT play a significant role in evaluating efficacy by providing detailed information about tumor activity.

5.2 Analysis of Short-term and Long-term Efficacy

Short-term efficacy typically refers to the early treatment response after transplantation, such as CR and PR rates within the first 100 days. This early assessment can quickly gauge the initial impact of Auto-HSCT and guide subsequent treatments. Long-term efficacy focuses on progression-free survival (PFS) and overall survival (OS) of patients, with data usually analyzed at 1 year, 3 years, or even longer post-transplant to evaluate the durability of the treatment and potential long-term survival benefits.

5.3 Factors Influencing Efficacy

The efficacy of Auto-HSCT is influenced by numerous factors, including patient age, baseline health status, disease stage, pathological subtype, IPI score, treatment history, and disease burden prior to transplantation. Additionally, specific factors during the transplantation process, such as the intensity of the conditioning regimen, the quantity and quality of stem cells, and management of post-transplant complications, can also impact outcomes. By analyzing these factors comprehensively, clinicians can better understand individual variations in treatment response and provide personalized treatment recommendations.

In evaluating efficacy, it is also crucial to distinguish between short-term and long-term complications associated with Auto-HSCT, such as infections, and organ dysfunction. These complications not only affect efficacy assessment but are also significant determinants of patient quality of life and long-term prognosis. Therefore, efficacy evaluation should comprehensively consider clinical response, complication risks, and patient quality of life.

6. Complications and Risk Management of Autologous Hematopoietic Stem Cell Transplantation

6.1 Identification of Common Complications

Although autologous hematopoietic stem cell transplantation (Auto-HSCT) avoids the risk of graft-versus-host disease (GVHD), various complications can still occur. Common complications include infections (bacterial, viral, or fungal due to leukopenia), bleeding tendencies (due to thrombocytopenia), organ dysfunction (liver, kidney, heart, lung), catheter-related complications (such as infections or thrombosis), and delayed immune reconstitution post-transplant[6]. Additionally, patients may experience late-onset complications, such as endocrine issues, secondary malignancies, or chronic GVHD.

6.2 Risk Management Strategies

Risk management strategies aim to reduce the incidence and severity of complications related to Auto-HSCT. These strategies include:

- Comprehensive patient assessment before conditioning to optimize overall health.
- Selecting individualized conditioning regimens to balance efficacy and toxicity.
- Strict aseptic procedures during transplantation to minimize infection risk.
- Monitoring blood counts and administering timely transfusions or platelet support to manage bleeding tendencies.
- Closely monitoring organ function and providing supportive care as needed.
- Prophylactic use of antibiotics, antivirals, and antifungals.
- Educating patients to enhance their awareness and self-management of complications.

6.3 Patient Follow-up and Quality of Life Assessment

Follow-up is crucial for evaluating the long-term effects of Auto-HSCT and monitoring late-onset complications. The follow-up plan should include regular clinical examinations, hematological assessments, imaging evaluations, and functional assessments. Additionally, quality of life assessment is an important component of follow-up, involving comprehensive evaluations of the patient's physical, psychological, and social adaptation. Surveys, psychological

counseling, and support groups can help patients cope with post-transplant life challenges and improve their overall well-being[7].

Quality of life assessments also provide feedback to the medical team, helping optimize treatment protocols and rehabilitation plans. For instance, addressing patient-reported issues such as fatigue, emotional fluctuations, or social isolation can lead to targeted interventions like nutritional support, psychological therapy, or social work services.

In conclusion, managing Auto-HSCT complications requires a multidisciplinary team effort, including hematologists, transplant coordinators, infection control experts, dietitians, physical therapists, and psychologists. Through proactive identification, prevention, and intervention strategies, the patient's transplant experience and long-term prognosis can be significantly improved.

7. Combined Application of Autologous Hematopoietic Stem Cell Transplantation with Other Treatment Methods

7.1 Combination with Chemotherapy

Autologous hematopoietic stem cell transplantation (Auto-HSCT) is often combined with chemotherapy to enhance the therapeutic effects on malignant tumors. Before transplantation, patients typically undergo high-dose chemotherapy as a conditioning regimen, aiming to eliminate as many cancer cells as possible and create optimal conditions for stem cell transplantation. Additionally, chemotherapy may be used post-transplant as consolidation therapy to further reduce the risk of relapse[8]. The choice of chemotherapy regimen should be based on the patient's disease characteristics, prior treatment response, and tolerance.

7.2 Combination with Targeted Therapy

Targeted therapy drugs aim at specific molecular markers of tumor cells, improving treatment efficacy while minimizing damage to normal cells. In the context of Auto-HSCT, targeted therapy can be used as a bridging treatment before and after transplantation to control disease progression and increase remission rates. For example, for certain PTCL subtypes, monoclonal antibodies targeting specific cell surface markers can be utilized for targeted therapy.

7.3 Combination with Immunotherapy

Immunotherapy, particularly chimeric antigen receptor T-cell (CAR-T) therapy and immune checkpoint inhibitors, is revolutionizing the treatment landscape of certain lymphomas. The combined application of Auto-HSCT and immunotherapy is an emerging strategy that leverages the power of the immune system to attack tumor cells. For instance, CAR-T cell therapy can be used pre-transplant to reduce tumor burden or post-transplant to enhance long-term remission rates. Immune checkpoint inhibitors may be used after transplantation to boost the patient's immune response against the tumor.

Comprehensive Treatment Strategy

The combined application of Auto-HSCT with other treatment methods requires careful consideration of various factors, including the timing, sequence, and potential interactions of treatments. For instance, targeted or immunotherapy may be used pre-transplant to increase the likelihood of achieving a better remission state, or post-transplant to consolidate the effect and prevent relapse. This combined treatment strategy needs to be rigorously evaluated in clinical trials to determine its safety and efficacy, and to provide personalized treatment options for patients.

During the implementation of a combined treatment regimen, the medical team must closely monitor the patient's response and any potential side effects, adjusting the treatment plan promptly to optimize efficacy and safety. This multidisciplinary, comprehensive approach can offer more thorough treatment strategies for patients with peripheral T-cell lymphoma, improving their prognosis and quality of life.

8. Research Progress and Future Directions

8.1 Limitations of Current Research

Despite the potential of autologous hematopoietic stem cell transplantation (Auto-HSCT) in the treatment of peripheral T-cell lymphoma (PTCL), existing studies have limitations. These include small sample sizes, a lack of randomized controlled trials, selection bias, and insufficient follow-up periods. Additionally, further research is needed on the timing of transplantation, standardization of conditioning regimens, and evaluation of long-term complications. For certain PTCL subtypes, the efficacy of Auto-HSCT remains unclear, necessitating more targeted studies to explore optimal treatment strategies.

8.2 Emerging Research and Technological Advances

Recent years have seen significant advancements in PTCL treatment through emerging research and technologies. For instance, the development of novel targeted and immunotherapy drugs offers more treatment options for PTCL patients. Research in genomics and proteomics helps better understand the molecular mechanisms of PTCL, guiding personalized therapy. Moreover, innovative therapies such as CAR-T cell therapy and bispecific antibodies have shown remarkable efficacy in certain lymphoma subtypes and may be combined with Auto-HSCT in the future to enhance treatment outcomes.

8.3 Future Research Directions and Outlook

Future research should focus on the following key areas:

- Personalized treatment strategies: Developing individualized treatment plans based on patients' genomic and

phenotypic characteristics.

- Integration of new drugs and therapies: Exploring how to combine emerging targeted drugs, immunotherapies, and cell therapies with Auto-HSCT to improve efficacy.
- Optimization of transplantation techniques and regimens: Investigating ways to improve conditioning regimens and transplantation techniques to reduce complications and increase engraftment rates.
- Long-term follow-up and quality of life studies: Conducting long-term follow-up studies to assess the impact of Auto-HSCT on patients' quality of life.
- Economic evaluation and health policy: Assessing the cost-effectiveness of Auto-HSCT in different healthcare systems to inform health policy decisions.

Looking ahead, as understanding of the biological characteristics of PTCL deepens and treatment technologies advance, Auto-HSCT is expected to play a greater role in the context of personalized and precision medicine. Through interdisciplinary collaboration and international multi-center research, the development and validation of new therapies can be accelerated, ultimately improving the prognosis of PTCL patients.

9. Conclusion

9.1 The Role of Autologous Hematopoietic Stem Cell Transplantation in PTCL Treatment

Autologous hematopoietic stem cell transplantation (Auto-HSCT) has established its significant role in the treatment of peripheral T-cell lymphoma (PTCL) for specific patient groups. For patients achieving remission after first-line treatment, Auto-HSCT provides an effective consolidation therapy to prolong progression-free survival and increase overall survival rates. Additionally, for relapsed or refractory PTCL patients, Auto-HSCT is a potential salvage treatment option. Despite certain risks and complications, careful patient selection, risk assessment, and management can lead to significant clinical benefits.

9.2 Key Findings of the Study

The main findings of this study include:

- Auto-HSCT can improve the survival rates of PTCL patients, especially those undergoing transplantation after achieving initial remission.
- Transplant-related complications can be effectively controlled through appropriate management and risk assessment strategies.
- Personalized treatment strategies, including the optimization of conditioning regimens and timing of transplantation, are crucial for enhancing the efficacy of Auto-HSCT.
- Emerging treatments such as targeted therapy and immunotherapy, when combined with Auto-HSCT, show potential for improving therapeutic outcomes.

9.3 Recommendations for Clinical Practice

Based on the findings of this study, the following recommendations are made for clinical practice:

Strengthen multidisciplinary team collaboration to develop individualized Auto-HSCT treatment plans for each PTCL patient.

- Conduct comprehensive assessments of the patient's disease status, physical fitness, and risk factors before transplantation to determine the optimal timing and conditioning regimen.
- Closely monitor patient recovery and potential complications post-transplantation, and take timely intervention measures.
- Explore the combined application of Auto-HSCT with other emerging treatments, such as targeted therapy and immunotherapy, to enhance therapeutic outcomes.
- Enhance patient education to increase their awareness of the treatment process, potential complications, and self-management.
- Encourage participation in clinical trials to evaluate the safety and efficacy of new therapies and promote innovation and development in PTCL treatment.

In conclusion, Auto-HSCT has been recognized as a valuable component of the comprehensive treatment strategy for PTCL. Future research and clinical practice should continue to explore ways to improve efficacy and safety while focusing on the overall well-being and quality of life of patients.

References

[1] JIANG M L, BENNANI N N, FELDMAN A L. Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms. Expert Rev Hematol, 2017, 10(3): 239-249

[2] WU G Q, LEI Y H, SUN Y, et al. High dose radiotherapy and chemotherapy combined with autologous bone marrow transplantation in the treatment of adult advanced highly malignant T-cell non-Hodgkin's lymphoma. Chin J Oncol, 1993, 15(1): 47-51.

[3] SHI Y K, SUN Y. Review of autologous hematopoietic stem cell transplantation for malignant solid tumors in China for 25 years. Natl Med J China, 2015, 95(10): 721-726.
[4] COLITA A, COLITA A, BUMBEA H, et al. LEAM vs BEAM vs CLV conditioning regimen for autologous stem cell transplantation in malignant lymphomas. Retrospective comparison of toxicity and efficacy on 222 patients in the first 100 days after transplant, on behalf of the Romanian Society for Bone Marrow Transplantation. Front Oncol, 2019, 9: 892.
[5] .Chinese Society of Clinical Oncology. Guidelines for diagnosis and treatment of lymphoma (2021). Beijing, People's Medical Publishing House: 1-292.
[6] XU L P, LU P H, WU D P, et al. Hematopoietic stem cell transplantation activity in China 2019: a report from the Chinese Blood and Marrow Transplantation Registry Group. Bone Marrow Transplant, 2021, 56(12): 2940-2947.
[7] HE X, JI J, MA C R, et al. Effect of fludarabine combined with BEAM pretreatment autologous peripheral blood stem cell transplantation in the treatment of non-Hodgkin's lymphoma. Int J Transplant Blood Purification, 2017, 15(5): 24-27.
[8] GUO Zhi, CHEN Huiren, LIU Xiaodong, et al. Clinical analysis of allogeneic hematopoietic stem cell transplantation for Hodgkin's lymphoma first autologous stem cell transplant relapse. The Practical Journal of Cancer, 2012, 27(5): 478-481.